FDA Publishes Guidance on Interchangeability of Protein Products
The guidance will assist sponsors in demonstrating a proposed therapeutic protein product is interchangeable with a reference product.
FDA released guidance in May 2019 to help sponsors demonstrate that a proposed therapeutic protein product is interchangeable with a reference product when submitting a marketing application or supplement under 351(k) of the Public Health Services Act. The guidance provides an overview of scientific considerations and discusses the type and amount of data needed to support interchangeability.
Specifically, the guidance addresses product-dependent factors such as product complexity and immunogenicity risk. Biosimilar postmarketing data are also discussed. FDA also details considerations for switching studies to support demonstration of interchangeability including study endpoints, study design and analysis, study population, conditions of use, and route of administration. Also discussed in the guidance are the development of presentations for proposed interchangeable products and postmarketing safety monitoring.
Source: FDA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
